These are likely mechanisms by which GLP-1 may impact neuropsychiatric conditions.” — Ziyad Al-Aly, MD “I think there is clearly (an) added benefit for several conditions. For example ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... were likely driven by two main mechanisms of action -- the first being a reduction in ...

Amanda Bonello – who lives in Iowa – decided to take action. “I haven't seen any ... more than 15,000 clients with compounded GLP-1. “Compounded products are very clean, very simple ...

Association does not imply causation, and the mechanism of action of these agents ... of patients who filled a prescription for a GLP-1 within at least 90 days before and after surgery and ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for inflammatory diseases. COYA 303 is an investigational biologic combination ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...